See more : Abaxx Technologies Inc. (ABXXF) Income Statement Analysis – Financial Results
Complete financial analysis of Aura Biosciences, Inc. (AURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aura Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Banca Profilo S.p.A. (PRO.MI) Income Statement Analysis – Financial Results
- Anant Raj Limited (ANANTRAJ.NS) Income Statement Analysis – Financial Results
- Advaxis, Inc. (ADXSD) Income Statement Analysis – Financial Results
- Avivagen Inc. (VIV.V) Income Statement Analysis – Financial Results
- Hawaiian Electric Industries, Inc. (HE) Income Statement Analysis – Financial Results
Aura Biosciences, Inc. (AURA)
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| Gross Profit | -1.30M | -1.18M | -835.00K | -831.00K | -509.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.23M | 42.24M | 25.16M | 18.04M | 19.62M |
| General & Administrative | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Other Expenses | 0.00 | -5.00K | -11.00K | 3.00K | -44.00K |
| Operating Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Cost & Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Interest Income | 0.00 | 1.86M | 13.00K | 3.00 | 5.00 |
| Interest Expense | 0.00 | 0.00 | 13.00K | 3.00K | 5.00K |
| Depreciation & Amortization | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| EBITDA | -83.70M | -59.12M | -34.42M | -21.38M | -23.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.99M | -60.30M | -35.25M | -22.21M | -24.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.72M | 1.53M | -1.00K | 0.00 | -60.00K |
| Income Before Tax | -76.27M | -58.76M | -35.25M | -22.21M | -24.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 137.00K | -1.53M | -830.00K | 3.00K | 5.00K |
| Net Income | -76.41M | -57.23M | -34.42M | -22.21M | -24.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| EPS Diluted | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| Weighted Avg Shares Out | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
| Weighted Avg Shares Out (Dil) | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate...
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024 Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time...
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights
Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024
Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 162.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive...
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a...
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON,...
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive...
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31,...
Source: https://incomestatements.info
Category: Stock Reports